Please try another search
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Enrique A. Conterno | 56 | 2023 | Member of Advisory Board |
Elaine Sullivan | 62 | 2023 | Member of Advisory Board |
Katja Hansen | - | 2024 | Alternate Director |
Adam Nygaard | - | 2024 | Employee Representative |
Tanja Erichsen | - | 2024 | Alternate Director |
Ludovic Otterbein | - | 2024 | Employee Representative |
Cecilie Kold | - | - | Alternate Director |
Lars Pedersen | - | 2024 | Alternate Director |
Iben Louise Gjelstrup | 47 | 2020 | Employee Representative Director |
Nikolaj Frederik Barfoed Beck | 57 | 2020 | Employee Representative Director |
Bernadette Mary Connaughton | 66 | 2019 | Independent Director |
Kirsten Aarup Drejer | 68 | 2018 | Independent Vice Chairman |
Leonard Kruimer | 66 | 2019 | Independent Director |
Anneline Nansen | 55 | 2021 | Employee Representative Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review